recombinant human erythropoietin biosimilar - LARVOL DELTA

Successful Treatment of Anemia with Roxadustat in a Hemodialysis Patient Following Erythropoietin-Induced Pure Red Cell Aplasia (KIDNEY WEEK 2023) - "In July 2021, shortly before he began dialysis, he was commenced rHuEPO (Jimaixin, epoetin-α, KexingBio, Shandong, China) subcutaneously 5000 IU twice a week. Anti EPO Ab assay is not always positive in EPO Ab-induced PRCA. Our case illustrates that treatment with Cyclosporin and a switch to Roxadustat are useful in treating EPO Ab-induced PRCA."

Clinical • Anemia • Diabetes • Diabetic Nephropathy • Hematological Disorders • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases • Solid Tumor • Thymoma • Thymus Cancer • Transplantation

Detection of recombinant erythropoietin biosimilar Jimaixin after administration in healthy subjects. (PubMed, Drug Test Anal) - "The effect of Jimaixin on hematological parameters was limited to a clear but transitory increase of the reticulocytes. These data give new elements to better survey a potential misuse of Jimaixin by athletes."

Clinical • Journal • Hematological Disorders

Evaluation of erythropoietin biosimilars Epotin™, Hemax® and Jimaixin™ by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex®. (PubMed, J Pharm Biomed Anal) - "Jimaixin™ and Epotin™ presented also a lower amount of fully sialylated forms. HILIC method also showed that O-acetylation level of sialic acid residues might vary from one rEPO to the other."

Journal • EPO